2023
Dyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study
Hosier H, Lipkind H, Rasheed H, DeWan A, Rogne T. Dyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study. Hypertension 2023, 80: 1067-1076. PMID: 36883459, DOI: 10.1161/hypertensionaha.122.20426.Peer-Reviewed Original ResearchConceptsRisk of preeclampsiaProtective effectCholesteryl Ester Transfer Protein InhibitionLack of effectMendelian randomization studyMendelian randomization analysisMaternal morbidityElevated HDLLeading causeLipid levelsObservational studyPreeclampsiaLipid measurementsReduced riskAncestry groupsPharmacological targetsRandomization studyHDLLDLRandomization analysisSingle nucleotide polymorphismsNew targetsDyslipidemiaRiskProtein inhibition
2019
Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction
Sposito A, de Lima-Junior J, Moura F, Barreto J, Bonilha I, Santana M, Virginio V, Sun L, Carvalho L, Soares A, Nadruz W, Feinstein S, Nofer J, Zanotti I, Kontush A, Remaley A. Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction. Arteriosclerosis Thrombosis And Vascular Biology 2019, 39: 1550-1564. PMID: 31189429, DOI: 10.1161/atvbaha.119.312880.Peer-Reviewed Original ResearchConceptsMyocardial infarctionHigh-density lipoproteinSphingosine-1-PhosphateSpectrum of signaling pathwaysEndothelin-1Cardiac functionCardioprotective benefitsTherapeutic advancesClinical studiesIschemia/reperfusion injuryProinflammatory moleculesAnimal modelsInsulin sensitivityHDLInfarctionMitochondrial channelsFunctional changesOxidative stressSignaling pathway
2017
Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-Lowering TherapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline
2016
Micro-RNAs and High-Density Lipoprotein Metabolism
Canfrán-Duque A, Lin CS, Goedeke L, Suárez Y, Fernández-Hernando C. Micro-RNAs and High-Density Lipoprotein Metabolism. Arteriosclerosis Thrombosis And Vascular Biology 2016, 36: 1076-1084. PMID: 27079881, PMCID: PMC5315356, DOI: 10.1161/atvbaha.116.307028.BooksConceptsReverse cholesterol transportCardiovascular diseaseHDL metabolismCholesterol transportIschemic heart diseaseCause of deathEarlier epidemiological studiesPotential therapeutic targetBile acid synthesisMicro-RNAsCardioprotective effectsHeart diseaseEpidemiological studiesImproved preventionCholesterol effluxTherapeutic targetDensity lipoproteinCholesterol uptakeDiseaseArtery wallHDL biogenesisInverse correlationHDLLiverAcid synthesis
2011
CYP4A11 variant is associated with high-density lipoprotein cholesterol in women
White CC, Feng Q, Cupples LA, Gainer JV, Dawson EP, Wilke RA, Brown NJ. CYP4A11 variant is associated with high-density lipoprotein cholesterol in women. The Pharmacogenomics Journal 2011, 13: 44-51. PMID: 21912424, PMCID: PMC3380161, DOI: 10.1038/tpj.2011.40.Peer-Reviewed Original ResearchConceptsHigh-density lipoprotein cholesterolFramingham Offspring StudyEpoxyeicosatrienoic acidsLipoprotein cholesterolLow HDLOffspring StudyHDL-C concentrationsCYP4A11 variantsMetabolic parametersPPARα activationEndogenous peroxisomeHDLBioVU cohortWomenReduced activityΩ-hydroxylaseCohortCYP4A11CholesterolPrevalenceGenotypes
2009
Peer‐counseling and inflammatory markers in Latinos diagnosed with type 2 diabetes. Results from the DIALBEST trial
Calle M, Vega‐Lopez S, Puglisi M, Segura‐Pérez S, Chhabra J, Pérez‐Escamilla R, Volek J, Fernandez M. Peer‐counseling and inflammatory markers in Latinos diagnosed with type 2 diabetes. Results from the DIALBEST trial. The FASEB Journal 2009, 23: 910.3-910.3. DOI: 10.1096/fasebj.23.1_supplement.910.3.Peer-Reviewed Original ResearchType 2 diabetesControl groupInflammatory markersIL-6Peer counselingMo of interventionTNF-alpha levelsStandard of careStatin useHDL cholesterolDietary recallsPlasma lipidsMacronutrient intakeHartford HospitalPC groupReductase inhibitorsAdiponectinLatino subjectsBaselineSoluble fiberDiabetesLeptinCRPHDLTrials
2008
Three‐month effect of diabetes peer counseling on plasma lipids of Latinos enrolled in the DIALBEST trial: Preliminary findings.
Vega‐López S, Calle M, Fernandez M, Chhabra J, D’Agostino D, Samuel G, Segura‐Pérez S, Damio G, Pérez‐Escamilla R. Three‐month effect of diabetes peer counseling on plasma lipids of Latinos enrolled in the DIALBEST trial: Preliminary findings. The FASEB Journal 2008, 22: 44.8-44.8. DOI: 10.1096/fasebj.22.1_supplement.44.8.Peer-Reviewed Original ResearchType 2 diabetesPlasma lipidsPC groupControl groupLDL/HDL ratioThree-month effectsStandard of carePC interventionsHDL ratioLatino patientsDiabetes careHartford HospitalPeer counseling servicesHealth disparitiesEliminating Health DisparitiesDlPeer counselingSelf-ManagementBaselineDiabetesLDLHDLAdditional yearPreliminary findingsMonths
2006
Th-P16:262 The capacity of HDL to stimulate cholesterol efflux is maintained in subjects with and without low HDL-C treated with torcetrapib
Bamberger M, Moya M, Durham K, Shear C, Nguyen T, Revkin J, Rothblat G. Th-P16:262 The capacity of HDL to stimulate cholesterol efflux is maintained in subjects with and without low HDL-C treated with torcetrapib. Atherosclerosis Plus 2006, 7: 550. DOI: 10.1016/s1567-5688(06)82220-8.Peer-Reviewed Original Research
1998
Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL
Calvo D, Gómez-Coronado D, Suárez Y, Lasunción M, Vega M. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. Journal Of Lipid Research 1998, 39: 777-788. PMID: 9555943, DOI: 10.1016/s0022-2275(20)32566-9.Peer-Reviewed Original ResearchConceptsHigh-affinity receptorHuman CD36Lipoprotein HDLAffinity receptorPathogenesis of atherosclerosisLow-density lipoproteinFoam cell formationBinding of lipoproteinsFatty acid metabolismSR-BIActive fatty acid metabolismDensity lipoproteinModified lipoproteinsScavenger receptorsLipid metabolismCD36CLA-1Monoclonal antibodiesLDLLipoproteinHDLAcid metabolismReceptorsVLDLNative lipoproteins
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply